Table 3 |
||||||
|
Baseline intake of medications in each cohort |
||||||
|
N = 251/group |
Group A (RA) |
Group B (DM) |
Group C (GP) |
P, all three |
P, A versus C |
|
|
|
||||||
|
Medications |
||||||
|
|
||||||
|
RA |
MTX |
126 (50%) |
N/A |
N/A |
-- |
-- |
|
HCQ |
92 (37%) |
N/A |
N/A |
-- |
-- |
|
|
PDN |
86 (34%) |
N/A |
N/A |
-- |
-- |
|
|
TNF |
96 (38%) |
N/A |
N/A |
-- |
-- |
|
|
|
||||||
|
DM |
Insulin |
N/A |
100 (40%) |
N/A |
-- |
-- |
|
Metformin |
N/A |
132 (53%) |
N/A |
-- |
-- |
|
|
|
||||||
|
NSAIDs |
74 (29%) |
43 (17%) |
51 (20%) |
0.003 |
0.02 |
|
|
|
||||||
|
Anti-HTN |
66 (26%) |
180 (72%) |
86 (34%) |
< 0.0001 |
0.052 |
|
|
|
||||||
|
Statin |
23 (9%) |
162 (65%) |
38 (15%) |
< 0.0001 |
0.055 |
|
|
|
||||||
|
ASA |
81 mg |
22 (9%) |
93 (37%) |
33 (13%) |
< 0.0001 |
0.12 |
|
> 81 mg |
5 (2%) |
16 (6%) |
6 (2%) |
0.01 |
0.76 |
|
|
|
||||||
|
Anti-HTN, antihypertensives; ASA, aspirin; DM, diabetes mellitus; GP, general population; HCQ, hydroxychloroquine; LEF, leflunomide; MTX, methotrexate; N/A, not applicable; NSAIDs, nonsteroidal antiinflammatory drugs; PDN, prednisone; RA, rheumatoid arthritis; TNF, anti-TNF agents. |
||||||
|
Desai et al. Arthritis Research & Therapy 2012 14:R270 doi:10.1186/ar4118 |
||||||
